IP Library Granted Patent US 9,393,210
Granted Patent B2
US 9,393,210 · App. 14/575,454 · Granted Jul 19, 2016

Capsules containing high doses of levodopa for pulmonary use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,393,210
App. No.
14/575,454
Granted
Jul 19, 2016
Kind
B2
Abstract

The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.

Claims (15)

1. A capsule for use in an inhalation device, wherein the capsule is filled with a dry powder comprising levodopa; wherein the capsule's shell comprises hydroxypropyl methylcellulose and titanium dioxide, and wherein the dry powder comprises a fine particle fraction of at least 50% of the nominal powder dose.

2. The capsule of claim 1 , wherein the dry powder comprises from about 2% to about 8% of water by weight.

3. The capsule of claim 2 , wherein the dry powder comprises from about 5% to about 6% of water by weight.

4. The capsule of claim 1 , wherein the capsule is a 00 size capsule.

5. The capsule of claim 4 , wherein the dry powder comprises between about 15 milligrams and 50 milligrams of levodopa.

6. The capsule of claim 5 , wherein the dry powder comprises between about 25 milligrams and 35 milligrams of levodopa.

7. The capsule of claim 1 , wherein the dry powder further comprises a salt.

8. The capsule of claim 7 , wherein said salt is sodium chloride.

9. The capsule of claim 1 , wherein the dry powder further comprises a phospholipid.

10. The capsule of claim 9 , wherein said phospholipid is dipalmitoylphosphatidylcholine (DPPC).

11. The capsule of claim 1 , wherein the dry powder further comprises DPPC and sodium chloride.

12. The capsule of claim 1 , wherein the dry powder comprises a fine particle fraction between about 50% to about 70% of the total amount of powder in the capsule.

13. The capsule of claim 1 , wherein the capsule is filled with about 30 milligrams to about 50 milligrams of dry powder.

14. The capsule of claim 1 , wherein the dry powder has a working density between about 0.02 g/cm 3 to about 0.1 g/cm 3 .

15. The capsule of claim of claim 1 , wherein the dry powder has a working density between about 0.02 g/cm 3 to about 0.05 g/cm 3 .

Assignments (4)
NUNC PRO TUNC ASSIGNMENT Recorded Jan 6, 2025
From: CIVITAS THERAPEUTICS, INC.
To: MERZ PHARMACEUTICALS, LLC
Reel/Frame 069752/0843 →
SECURITY INTEREST Recorded Dec 23, 2019
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 051403/0954 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →